Disease overview

Alterations

130

Molecular (A)

100

Clinical (B–E)

Direct drugs

Via biomarker

397

Natural agents

Natural products

Merged ranked

431

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, Seeds, GreenMedInfo · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Spontaneous remission at 1 year: ~50%; at 5 years: ~65-70%; but 10-15% remain chronic beyond 5 years; remission followed by relapse common

Best-intervention remission

Omalizumab (anti-IgE): complete symptom resolution in 36-44% at 12 weeks (GLACIAL, ASTERIA trials); high-dose antihistamines (4x standard dose): 50-60% symptom control; cyclosporine for antihistamine-refractory: 50-60% response; dupilumab for CSU: 73% UAS7 ≤6 at 24 weeks (Phase 3 LIBERTY-CSU CUPID 2023)

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Moderate — omalizumab is transformative but not accessible as first-line; many patients on inadequate antihistamine doses or antihistamine monotherapy long-term

Primary barrier

access/practice

Barrier detail: Omalizumab (Xolair) was FDA-approved for CSU in 2014 but remains unavailable as first-line (prior authorisation requiring antihistamine failure first); many patients spend years on sedating antihistamines or systemic OCS; dupilumab (2023 Phase 3 data) adds a second biologic option

Last SoC change: 2023 — dupilumab Phase 3 LIBERTY-CSU CUPID positive (likely approval pending); 2014 omalizumab approved for CSU; cetirizine/fexofenadine as first-line since 1990s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0044212 · ORPHA: ORPHA:313800

Alterations

Showing 80 of 130 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
ADRA1A adrenoceptor alpha 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1B adrenoceptor alpha 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA1D adrenoceptor alpha 1D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2A adrenoceptor alpha 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2B adrenoceptor alpha 2B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRA2C adrenoceptor alpha 2C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB1 adrenoceptor beta 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB2 adrenoceptor beta 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADRB3 adrenoceptor beta 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AK006 Anti-drug Antibodies (ADAs)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
AK006 serum concentrations	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Area Under the Concentration-time Curve From Time 0 to 24 Hours (AUC [0-24]) of GSK2646264 for Part A	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BDNF brain derived neurotrophic factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BMX BMX non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BTK Bruton tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C5AR1 complement C5a receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CACNA1C calcium voltage-gated channel subunit alpha1 C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCL2 C-C motif chemokine ligand 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCL5 C-C motif chemokine ligand 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD4 CD4 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD40LG CD40 ligand	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD8A CD8 subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CLU clusterin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CNR1 cannabinoid receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CRP C-reactive protein	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CXCL8 C-X-C motif chemokine ligand 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change From Baseline in Electrocardiogram (ECG) Parameters for Part A	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Vital Sign Parameter Heart Rate for Part A	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Weekly Hives Severity Score at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Weekly Hives Severity Score at Week 24	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Weekly Itch Severity Score at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Weekly Itch Severity Score at Week 24	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Weekly Urticaria Activity Score at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in Weekly Urticaria Activity Score at Week 24	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
Change From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Week 12	Scales & PROs	Clinical scale	—	—	Emerging	ClinicalTrials.gov	—
DHFR dihydrofolate reductase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ECG parameters from baseline	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
ENPP3 ectonucleotide pyrophosphatase/phosphodiesterase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FASLG Fas ligand	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FCER1A Fc epsilon receptor Ia	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FCER2 Fc epsilon receptor II	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HRAS HRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
HRH1 histamine receptor H1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNG interferon gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IGHE immunoglobulin heavy constant epsilon	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL10 interleukin 10	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL13 interleukin 13	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL17A interleukin 17A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL18 interleukin 18	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL1B interleukin 1 beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2 interleukin 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RA interleukin 2 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RB interleukin 2 receptor subunit beta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL2RG interleukin 2 receptor subunit gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL31 interleukin 31	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL33 interleukin 33	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL4R interleukin 4 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL5 interleukin 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL5RA interleukin 5 receptor subunit alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL6 interleukin 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IL9 interleukin 9	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
INS insulin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ITK IL2 inducible T cell kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
JAK3 Janus kinase 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KIT KIT proto-oncogene, receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MRGPRX2 MAS related GPR family member X2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Number of Participants With AEs and SAEs Defined by Severity Part A	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Number of Participants With Hematology Data Outside the Range of PCI for Part A	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
OSMR oncostatin M receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE10A phosphodiesterase 10A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE1A phosphodiesterase 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE1B phosphodiesterase 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE1C phosphodiesterase 1C	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE2A phosphodiesterase 2A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3A phosphodiesterase 3A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE3B phosphodiesterase 3B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4A phosphodiesterase 4A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PDE4B phosphodiesterase 4B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ACALABRUTINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACALABRUTINIB MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACEBUTOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACEBUTOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ADAPALENE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALBUTEROL SULFATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALFUZOSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BENZOATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE MALEATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARBUTAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ARFORMOTEROL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ARFORMOTEROL TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ARSENIC TRIOXIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASENAPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATENOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATIPAMEZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BACLOFEN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENZPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BEPRIDIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAXOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAXOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETHANIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BISOPROLOL FUMARATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BITOLTEROL MESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BORTEZOMIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRETYLIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BRIMONIDINE TARTRATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BROMOCRIPTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CABERGOLINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAMPTOTHECIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CAPSAICIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARBACHOL Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
CARTEOLOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
CARTEOLOL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets
CARVEDILOL Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	—
CARVEDILOL PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	No indexed hits View evidence CT.gov search · Cochrane · PubMed	DGIdb	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Sources	Links
BARZOLVOLIMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
BILASTINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
CHOLECALCIFEROL	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DESLORATADINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
DUPILUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LEVOCETIRIZINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
LIGELIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
METHOTREXATE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
OMALIZUMAB	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
OZUREPRUBART	Biologic	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
REMIBRUTINIB	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
RUPATADINE	Small molecule	Phase III	Moderate	80	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
AZD1981	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BENRALIZUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CANAKINUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CANNABIDIOL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
CILOSTAZOL	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
DIPYRIDAMOLE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
EPINEPHRINE	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
ETANERCEPT	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
FENEBRUTINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LESIGERCEPT	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
LIRENTELIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
POVORCITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
QUILIZUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
RILZABRUTINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
RITLECITINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TEZEPELUMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
TIRABRUTINIB	Small molecule	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
UCENPRUBART	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
VIXARELIMAB	Biologic	Phase II	Emerging	60	Open Targets	ChEMBL Open Targets
BRIQUILIMAB	Biologic	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets
MEPOLIZUMAB	Biologic	Phase I	Emerging	35	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Sources	Links
ACALABRUTINIB Repurposing via BTK	Small molecule	Approved	Strong	95	DGIdb	—
ACALABRUTINIB MALEATE Repurposing via BTK	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
ACEBUTOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
ACEBUTOLOL HYDROCHLORIDE Repurposing via ADRB1	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
ACETAZOLAMIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
ADAPALENE Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
ALBUTEROL SULFATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
ALFUZOSIN Repurposing via ADRA1B	Small molecule	Approved	Strong	95	DGIdb	—
ALFUZOSIN HYDROCHLORIDE Repurposing via ADRA1B	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
AMIODARONE HYDROCHLORIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	DGIdb	—
AMITRIPTYLINE HYDROCHLORIDE Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
AMLODIPINE BENZOATE Repurposing via CACNA1C	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
AMLODIPINE BESYLATE Repurposing via CACNA1C	Small molecule	Approved	Strong	95	DGIdb	—
AMLODIPINE MALEATE Repurposing via CACNA1C	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
APOMORPHINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
APRACLONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
APRACLONIDINE HYDROCHLORIDE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
ARBUTAMINE Repurposing via ADRB1	Small molecule	Approved	Strong	95	DGIdb	—
ARFORMOTEROL Repurposing via ADRB2	Small molecule	Approved	Strong	95	DGIdb	—
ARFORMOTEROL TARTRATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
ARGIPRESSIN Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
ARSENIC TRIOXIDE Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
ASENAPINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
ATENOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
ATIPAMEZOLE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
ATROPINE Repurposing via ADRA2A	Small molecule	Approved	Strong	95	DGIdb	—
BACLOFEN Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
BENZPHETAMINE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	DGIdb	—
BEPRIDIL HYDROCHLORIDE Repurposing via CACNA1C	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BETAXOLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
BETAXOLOL HYDROCHLORIDE Repurposing via ADRB1	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BETHANIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
BICALUTAMIDE Repurposing via ADRA1A	Small molecule	Approved	Strong	95	ChEMBL	ChEMBL Open Targets
BISOPROLOL Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—
BISOPROLOL FUMARATE Repurposing via ADRB1	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BITOLTEROL MESYLATE Repurposing via ADRB2	Small molecule	Approved	Strong	95	DGIdb	ChEMBL Open Targets
BORTEZOMIB Repurposing via BDNF	Small molecule	Approved	Strong	95	DGIdb	—
BRETYLIUM Repurposing via ADRB1	Small molecule	Approved	Strong	95	DGIdb	—
BRIMONIDINE Repurposing via ADRA2C	Small molecule	Approved	Strong	95	DGIdb	—

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Chronic Urticaria (CSU)

Disease overview

Remission & chronicity

Alterations

Therapeutics

Part of the Open Source Medicine Foundation Network